X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DR. REDDYS LAB - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DR. REDDYS LAB FRESENIUS KABI ONCO./
DR. REDDYS LAB
 
P/E (TTM) x 22.1 34.1 65.0% View Chart
P/BV x 3.1 3.3 93.2% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 FRESENIUS KABI ONCO.   DR. REDDYS LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DR. REDDYS LAB
Mar-17
FRESENIUS KABI ONCO./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1763,397 5.2%   
Low Rs792,560 3.1%   
Sales per share (Unadj.) Rs37.7856.5 4.4%  
Earnings per share (Unadj.) Rs5.178.0 6.5%  
Cash flow per share (Unadj.) Rs6.7139.9 4.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs42.5739.8 5.8%  
Shares outstanding (eoy) m158.23165.74 95.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.43.5 97.1%   
Avg P/E ratio x25.038.2 65.4%  
P/CF ratio (eoy) x18.921.3 88.9%  
Price / Book Value ratio x3.04.0 74.3%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m20,135493,632 4.1%   
No. of employees `0001.222.7 5.1%   
Total wages/salary Rs m70331,068 2.3%   
Avg. sales/employee Rs Th5,176.26,259.0 82.7%   
Avg. wages/employee Rs Th610.41,369.8 44.6%   
Avg. net profit/employee Rs Th699.6569.7 122.8%   
INCOME DATA
Net Sales Rs m5,963141,961 4.2%  
Other income Rs m181,715 1.0%   
Total revenues Rs m5,981143,676 4.2%   
Gross profit Rs m1,43024,722 5.8%  
Depreciation Rs m25810,266 2.5%   
Interest Rs m-26634 -4.1%   
Profit before tax Rs m1,21615,537 7.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,965 11.5%   
Profit after tax Rs m80612,921 6.2%  
Gross profit margin %24.017.4 137.7%  
Effective tax rate %28.119.1 147.4%   
Net profit margin %13.59.1 148.5%  
BALANCE SHEET DATA
Current assets Rs m5,10296,837 5.3%   
Current liabilities Rs m2,38584,199 2.8%   
Net working cap to sales %45.68.9 511.7%  
Current ratio x2.11.2 186.0%  
Inventory Days Days15073 204.5%  
Debtors Days Days11398 116.0%  
Net fixed assets Rs m5,148102,552 5.0%   
Share capital Rs m158829 19.1%   
"Free" reserves Rs m6,556121,792 5.4%   
Net worth Rs m6,732122,621 5.5%   
Long term debt Rs m9525,449 17.5%   
Total assets Rs m10,388218,165 4.8%  
Interest coverage x-45.825.5 -179.5%   
Debt to equity ratio x0.10 318.3%  
Sales to assets ratio x0.60.7 88.2%   
Return on assets %7.56.2 120.8%  
Return on equity %12.010.5 113.6%  
Return on capital %14.612.9 113.2%  
Exports to sales %74.554.6 136.4%   
Imports to sales %24.89.4 265.0%   
Exports (fob) Rs m4,44177,520 5.7%   
Imports (cif) Rs m1,47713,274 11.1%   
Fx inflow Rs m5,29881,670 6.5%   
Fx outflow Rs m1,77226,355 6.7%   
Net fx Rs m3,52555,315 6.4%   
CASH FLOW
From Operations Rs m1,27421,444 5.9%  
From Investments Rs m-1,204-18,404 6.5%  
From Financial Activity Rs m-196-3,692 5.3%  
Net Cashflow Rs m-126-1,144 11.0%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 9.6 35.3 27.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   42,599 75,885 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUN PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS